Board changes at Diageo

Diageo has announced the appointment of Emma Walmsley as a non-executive director effective January 1, 2016. 

Walmsley will also join the audit, the nomination and the remuneration committees. Diageo has also announced that Laurence Danon will step down at its upcoming AGM in September, having been on Diageo’s board for nine years. 

Walmsley is currently CEO of GSK Consumer Healthcare, a global joint venture between GSK and Novartis. As chief executive Walmsley is responsible for overseeing the world’s leading over-the-counter (OTC) healthcare company. During her tenure as chief executive, GSK Consumer Healthcare has become the leader in 36 markets as well as gaining a strong position in broader growth areas. Walmsley moved to GSK from L’Oreal where she worked in marketing and general management for 17 years.

Diageo chairman, Dr Franz Humer said: “I look forward to welcoming Emma to Diageo's board. She brings to Diageo a strong blend of commercial and marketing insight. She has significant experience in consumer products, and understands the consumer mindset and how to shape consumer trends. Her work across mature and fast developing countries will support us as we embed our expanded geographic footprint and maximise our strong platform for growth.
“I would also like to thank Laurence Danon for her contribution as a non-executive director over the last nine years.  Laurence has been a valued member of the board during a period of progress and growth for Diageo.”